Drugs / Inteferon Beta 1b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04469491 | Sep 2020 → Jun 2023 overdue | COVID-19, interferon antiviral depressor | Centre Hospitalier Universitaire, Amiens | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inteferon Beta 1b | “Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study” NCT04469491 ↗ |
| Modality | Protein / enzyme biologic | “Type I interferons (including IFN-α and IFN-β) are antiviral defence cytokines” NCT04469491 ↗ |
| Route | Inhaled | “inhaled interferon” NCT04469491 ↗ |